{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:18:24Z","timestamp":1771834704311,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rmed.2026.108697","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:11:29Z","timestamp":1770225089000},"page":"108697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Side versus adverse effects of elexacaftor\/tezacaftor\/ivacaftor therapy in people with CF"],"prefix":"10.1016","volume":"253","author":[{"given":"J.B.A.","family":"Gorgels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C.","family":"van der Hout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.W.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.G.M.","family":"Heijerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bronsveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108697_bib1","series-title":"Modifying Factors of Cystic Fibrosis Disease: Residual Chloride Secretion, Genetic Background and Epigenetics, Introduction","first-page":"7","author":"Bronsveld","year":"2000"},{"issue":"10059","key":"10.1016\/j.rmed.2026.108697_bib2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet."},{"issue":"10212","key":"10.1016\/j.rmed.2026.108697_bib3","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2026.108697_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"19","key":"10.1016\/j.rmed.2026.108697_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108697_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.108697_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2026.108697_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.rmed.2026.108697_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2026.108697_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-Gating and -Residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.rmed.2026.108697_bib11","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108697_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2023.03.005","article-title":"How representative are clinical trial cohorts of the general CF population? Implications for trial planning","volume":"23","author":"Dobra","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108697_bib13","first-page":"243","article-title":"Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma","volume":"10","author":"Walayat","year":"2017","journal-title":"Int. Med. Case Rep. J."},{"issue":"16","key":"10.1016\/j.rmed.2026.108697_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.rmed.2026.108697_bib15","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2026.108697_bib16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108697_bib17","article-title":"Effects of elexacaftor-tezacaftor-ivacaftor discontinuation in cystic fibrosis","volume":"82","author":"Mitropoulou","year":"2022","journal-title":"Respir Med Res"},{"issue":"1","key":"10.1016\/j.rmed.2026.108697_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010023","article-title":"Real-World safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108697_bib19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ppul.26217","article-title":"Outcome of elexacaftor\/tezacaftor\/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation","volume":"58","author":"\u00d8rum","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"173","key":"10.1016\/j.rmed.2026.108697_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0045-2024","article-title":"New drugs, new challenges in cystic fibrosis care","volume":"33","author":"Fajac","year":"2024","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2026.108697_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.rmed.2026.108697_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108697_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2026.108697_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2024.104236","article-title":"Efficacy of elexacaftor-tezacaftor-ivacaftor on chronic rhinosinusitis in cystic fibrosis","volume":"45","author":"Di Gioia","year":"2024","journal-title":"Am. J. Otolaryngol."},{"issue":"12","key":"10.1016\/j.rmed.2026.108697_bib25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoto.2023.2701","article-title":"Elexacaftor-Tezacaftor-Ivacaftor therapy for chronic sinus disease in cystic fibrosis","volume":"149","author":"Sheikh","year":"2023","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"issue":"3","key":"10.1016\/j.rmed.2026.108697_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108697_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.rmed.2026.108697_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112600065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112600065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:51:04Z","timestamp":1771833064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112600065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"alternative-id":["S095461112600065X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108697","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side versus adverse effects of elexacaftor\/tezacaftor\/ivacaftor therapy in people with CF","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108697"}}